These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 18318773)

  • 1. Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects.
    Kim BH; Lim HS; Chung JY; Kim JR; Lim KS; Sohn DR; Cho JY; Yu KS; Shin SG; Paick JS; Jang IJ
    Br J Clin Pharmacol; 2008 Jun; 65(6):848-54. PubMed ID: 18318773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers.
    Jung J; Choi S; Cho SH; Ghim JL; Hwang A; Kim U; Kim BS; Koguchi A; Miyoshi S; Okabe H; Bae KS; Lim HS
    Clin Ther; 2010 Jun; 32(6):1178-87. PubMed ID: 20637970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    Zhao C; Kim SW; Yang DY; Kim JJ; Park NC; Lee SW; Paick JS; Ahn TY; Min KS; Park K; Park JK
    Eur Urol; 2011 Aug; 60(2):380-7. PubMed ID: 21458153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction.
    Paick JS; Kim SW; Yang DY; Kim JJ; Lee SW; Ahn TY; Choi HK; Suh JK; Kim SC
    J Sex Med; 2008 Apr; 5(4):946-953. PubMed ID: 18221288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ketoconazole on the pharmacokinetics of udenafil in healthy Korean subjects.
    Shin KH; Chung YJ; Kim BH; Kim TE; Kim HS; Cho JY; Jang IJ; Shin SG; Yu KS
    Br J Clin Pharmacol; 2010 Mar; 69(3):307-10. PubMed ID: 20233203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of udenafil for the treatment of erectile dysfunction up to 12 hours after dosing: a randomized placebo-controlled trial.
    Park HJ; Park JK; Park K; Min K; Park NC
    J Sex Med; 2010 Jun; 7(6):2209-2216. PubMed ID: 20412426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of food on the pharmacokinetics of the oral phosphodiesterase 5 inhibitor udenafil for the treatment of erectile dysfunction.
    Kim TE; Kim BH; Kim JR; Lim KS; Hong JH; Kim KP; Kim HS; Shin SG; Jang IJ; Yu KS
    Br J Clin Pharmacol; 2009 Jul; 68(1):43-6. PubMed ID: 19660002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 3 Study to Evaluate the 1-Year Efficacy and Safety of Udenafil 75 mg Once Daily in Patients With Erectile Dysfunction.
    Moon KH; Kim SW; Moon du G; Kim JJ; Park NC; Lee SW; Paick JS; Ahn TY; Chung WS; Min KS; Park JK; Yang DY; Shin HS; Park K
    J Sex Med; 2016 Aug; 13(8):1263-9. PubMed ID: 27319276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic interaction between udenafil and dapoxetine: a randomized, open-labeled crossover study in healthy male volunteers.
    Kim YH; Choi HY; Lee SH; Jeon HS; Lim HS; Bahng MY; Bae KS
    Drug Des Devel Ther; 2015; 9():1209-16. PubMed ID: 25759565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of once-daily administration of udenafil for 24 weeks on erectile dysfunction: results from a randomized multicenter placebo-controlled clinical trial.
    Moon KH; Ko YH; Kim SW; Moon du G; Kim JJ; Park NC; Lee SW; Paick JS; Ahn TY; Chung WS; Min KS; Park JK; Yang DY; Park K
    J Sex Med; 2015 May; 12(5):1194-201. PubMed ID: 25736397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of udenafil in Turkish men with erectile dysfunction of psychogenic and organic aetiology: a randomized, double-blind, placebo-controlled study.
    Ortaç M; Çayan S; Çalişkan MK; Yaman MÖ; Okutucu TM; Semerci MB; Altay AB; Balbay MD; Özcan MF; Kadioğlu A
    Andrology; 2013 Jul; 1(4):549-55. PubMed ID: 23785019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Age on the Pharmacokinetics of Udenafil in Healthy Subjects.
    Choi HK; Jung JA; Shon J; Bahng MY; Cho DY; Yeo CW; Kim EY; Shin JG
    J Clin Pharmacol; 2016 Nov; 56(11):1372-1377. PubMed ID: 27006150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor-γ agonist: a single- and multiple-dose, double-blind, randomized control study in healthy male Korean subjects.
    Kim JW; Kim JR; Yi S; Shin KH; Shin HS; Yoon SH; Cho JY; Kim DH; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2011 Nov; 33(11):1819-30. PubMed ID: 22047812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability and pharmacokinetics of a new P-glycoprotein inhibitor, HM30181, in healthy Korean male volunteers: single- and multiple-dose randomized, placebo-controlled studies.
    Kim TE; Gu N; Yoon SH; Cho JY; Park KM; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2012 Feb; 34(2):482-94. PubMed ID: 22284902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
    Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Renal Impairment on the Pharmacokinetics and Safety of Udenafil.
    Cho YS; Noh YH; Lim HS; Cho SH; Ghim JL; Choe S; Kim SB; Park JS; Lee SK; Yang WS; Chang JW; Bahng MY; Bae KS
    J Clin Pharmacol; 2018 Jul; 58(7):905-912. PubMed ID: 29537612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of udenafil [Zydena] for the treatment of erectile dysfunction in hypertensive men taking concomitant antihypertensive agents.
    Paick JS; Kim SW; Park YK; Hyun JS; Park NC; Lee SW; Park K; Moon KH; Chung WS
    J Sex Med; 2009 Nov; 6(11):3166-76. PubMed ID: 19694927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.
    van Troostenburg AR; Clark EV; Carey WD; Warrington SJ; Kerns WD; Cohn I; Silverman MH; Bar-Yehuda S; Fong KL; Fishman P
    Int J Clin Pharmacol Ther; 2004 Oct; 42(10):534-42. PubMed ID: 15516022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic administration of udenafil, a selective phosphodiesterase type 5 inhibitor, promotes erectile function recovery in an animal model of bilateral cavernous nerve crush injury.
    Lee CH; Kim HS; Goo MJ; Kang KK; Ahn BO; Kim SH; Yang DY
    J Sex Med; 2011 May; 8(5):1330-40. PubMed ID: 21366883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.